Diagnostics company Guardant Health (NASDAQ: GH) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 36.1% year on year to $361 million. The company expects the full year’s revenue to be around $1.37 billion, close to analysts’ estimates. Its non-GAAP loss of $0.29 per share was 7.8% above analysts’ consensus estimates.

Is now the time to buy GH? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Guardant Health’s latest quarter saw revenue growth surpassing Wall Street expectations, but the market reacted negatively to the results. Management attributed the performance to robust adoption of Shield in cancer screening and continued expansion of the Guardant360 and Reveal oncology product lines. Co-CEO Helmy Eltoukhy highlighted the impact of FDA approval for Guardant360 CDx as a key milestone, enabling more frequent and precise therapy selection for breast cancer patients. However, despite broad-based revenue strength across oncology and screening, persistent operating losses and ongoing investments in commercial infrastructure likely contributed to investor caution.

Looking ahead, management’s guidance is shaped by aggressive expansion plans for Shield, ongoing productivity gains in the commercial team, and new product launches in oncology. Co-CEO AmirAli Talasaz pointed to the potential for broader patient access as coverage for Shield expands, saying, “100 million people are now covered for Shield CRC screening and have the option to receive MCD results through our clinical data initiative.” CFO Mike Bell noted cost per test reductions and automation investments as critical levers to support margin improvement and progress towards cash flow breakeven by the end of 2027.

Key insights from management’s remarks

Management identified strong product adoption, expanded payer coverage, and new regulatory approvals as the primary drivers of recent growth, while also acknowledging margin pressures and ongoing investment.

• Shield screening adoption: Exceptional growth in Shield screening was driven by expanded payer coverage, increased physician trust, and successful direct-to-consumer campaigns. Management cited a 246% year-over-year increase in Shield test volumes, with national and regional payers expanding access to over 100 million eligible patients.
• Oncology product momentum: The Guardant360 and Reveal portfolios experienced robust volume growth, supported by recent FDA approvals and product enhancements. The Guardant360 Liquid test saw nearly 30% volume growth, while Reveal volumes more than doubled as monitoring use cases expanded.
• Smart App launches: The fourth wave of oncology-focused Smart Apps, including new methylation-based predictors and immunotherapy selection tools, strengthened Guardant’s competitive position. Management expects these upgrades to further accelerate adoption by providing more actionable clinical insights from a single blood test.
• Workflow and cost improvements: Rapid implementation of automated Shield workflows and a shift to higher-throughput sequencing platforms reduced Shield’s cost per test by 20% sequentially, outpacing internal targets. These improvements contributed to stable gross margins despite a changing product mix.
• Coverage and reimbursement progress: Recent wins with national (UnitedHealthcare, Carelon, eviCore) and regional payers expanded Shield’s addressable market and underpinned higher revenue guidance. Management noted that while average selling prices (ASPs) remain above $800, they expect ASPs to moderate as the commercial mix grows, with long-term stabilization anticipated as more payers adopt Shield.

Drivers of future performance

Guardant Health’s future outlook rests on accelerating Shield adoption, new product launches, and ongoing efficiency gains, while navigating reimbursement dynamics and expanded commercial investments.

• Shield coverage expansion: Management believes recently secured and upcoming payer coverage will drive continued Shield volume growth. Broader access, especially from national insurers and legislative changes at the state level, is expected to increase test adoption, although the impact will materialize gradually over several quarters.
• Product innovation pipeline: The company’s upcoming clinical launch of Reveal Ultra and expanded Smart App features are expected to enhance the value proposition for both oncologists and biopharma partners. Management highlighted ongoing studies to extend Reveal’s clinical indications, aiming to capture a larger share of the therapy monitoring and MRD (minimal residual disease) markets.
• Margin and cash flow focus: CFO Mike Bell emphasized automation, cost reduction initiatives, and a planned inflection point in Shield’s commercial scale by 2027 as key to achieving company-wide cash flow breakeven. However, timing of certain payments (such as CMS adoption of new billing codes) and elevated operating expenses tied to expansion remain headwinds in the near term.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will be watching (1) whether Shield’s adoption continues to accelerate as coverage broadens and direct-to-consumer campaigns scale, (2) the pace of regulatory progress and reimbursement for new oncology products like Reveal Ultra and Guardant360 Tissue, and (3) the company’s ability to execute on automation and cost reduction targets. The progression of ASP trends and CMS billing code updates will also serve as important signposts for sustainable margin improvement.

Guardant Health currently trades at $137.26, down from $153.43 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.